Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
information fournie par Boursorama CP 14/11/2022 à 08:00

Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022

Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in a Phase I/IIa trial

Strasbourg, France, November 14, 2022, 08:00 am CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today announced that a paper co-authored by researchers from Transgene and BioInvent is the recipient of this year’s Journal for ImmunoTherapy of Cancer (JITC) “Best Oncolytic and Local Immunotherapy Paper” Award. The paper on BT-001 was highlighted at the annual Society for Immunotherapy of Cancer (SITC) conference being held November 8-12, 2022 in Boston, MA.

Valeurs associées

TRANSGENE
0,7530 EUR Euronext Paris -0,26%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
85,38 +2,47%
2CRSI
29,16 -1,15%
CAC 40
8 314,63 -0,60%
TOTALENERGIES
71,78 +1,93%
STELLANTIS
4,876 -1,11%
Chargement...

Pages les plus populaires

L'offre BoursoBank